Show simple item record

dc.contributor.authorHorton, William
dc.contributor.authorD'Amico, Kristina
dc.contributor.authorDavis, Stephanie
dc.contributor.authorSchafer, Christian
dc.contributor.authorBeck, Gregory
dc.contributor.authorTorok, Bela
dc.date2022-08-11T08:08:14.000
dc.date.accessioned2022-08-23T15:47:20Z
dc.date.available2022-08-23T15:47:20Z
dc.date.issued2014-05-20
dc.date.submitted2014-10-02
dc.identifier.doi10.13028/bgzc-p695
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27961
dc.description<p>Abstract of poster presented at the 2014 UMass Center for Clinical and Translational Science Research Retreat, held on May 20, 2014 at the University of Massachusetts Medical School, Worcester, Mass.</p>
dc.description.abstractParallel with the advancements in medical techniques and treatments, the microorganisms that we are constantly battling against are also evolving. Bacterial evolution is leading to an increasing number of antibiotic resistant strains of bacteria. As the bacteria evolve, the antibiotics that are currently in use to combat bacterial diseases are becoming ineffective. FDA approval of new antibacterial agents decreased drastically over the past decade. Thus the design and synthesis of new classes of antibacterial agents, possibly with structures unrelated to the current antibiotics, as the next generation antibacterial agents is highly desirable. In the current work the antimicrobial effect of an extended library of about 80 diarylhydrazones, related diaryl Schiff-bases and their precursor compounds, aryl-carbonyl compounds and phenylhydrazines have been evaluated against Escherichia coli, Micrococcus luteus and Staphylococcus aureus strains of bacteria. All compounds have been properly purified by recrystallization or column chromatography. The products were characterized by mass spectrometry and 1H, 13C and, when applicable, 19F NMR spectroscopy. While the diarylhydrazones and diaryl Schiff-bases were chosen due to their general biological activity, the carbonyl compounds and phenylhydrazines, that are their precursor compounds, were screened as possible metabolic products. Independent hydrolysis and mass spectrometric studies were also carried out under the generic assay conditions in order to determine the stability of the screened diarylhydrazones and Schiff-bases. The compounds have been tested in standard cytotoxicity assays using Escherichia coli, Micrococcus luteus and Staphylococcus aureus strains. It was observed that the diarylhydrazones showed considerable activity against all three bacterial strains, while the diaryl Schiff-bases exhibited moderate to weak activity. The precursor compounds appeared to be inactive against the bacteria. The stability studies also indicated that the hydrazones as well as the Schiff-bases remained stable under the assay conditions.
dc.formatyoutube
dc.language.isoen_US
dc.rightsCopyright the Author(s)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/
dc.subjectBacterial Infections and Mycoses
dc.subjectChemical and Pharmacologic Phenomena
dc.subjectOrganic Chemistry
dc.subjectTranslational Medical Research
dc.titleEvaluation of Antibiotic Properties of Diarylhydrazones, Diaryl Schiff-bases and Their Precursors
dc.typePoster Abstract
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1268&amp;context=cts_retreat&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/cts_retreat/2014/posters/48
dc.identifier.contextkey6199979
refterms.dateFOA2022-08-23T15:47:20Z
html.description.abstract<p>Parallel with the advancements in medical techniques and treatments, the microorganisms that we are constantly battling against are also evolving. Bacterial evolution is leading to an increasing number of antibiotic resistant strains of bacteria. As the bacteria evolve, the antibiotics that are currently in use to combat bacterial diseases are becoming ineffective. FDA approval of new antibacterial agents decreased drastically over the past decade. Thus the design and synthesis of new classes of antibacterial agents, possibly with structures unrelated to the current antibiotics, as the next generation antibacterial agents is highly desirable. In the current work the antimicrobial effect of an extended library of about 80 diarylhydrazones, related diaryl Schiff-bases and their precursor compounds, aryl-carbonyl compounds and phenylhydrazines have been evaluated against Escherichia coli, Micrococcus luteus and Staphylococcus aureus strains of bacteria. All compounds have been properly purified by recrystallization or column chromatography. The products were characterized by mass spectrometry and 1H, 13C and, when applicable, 19F NMR spectroscopy. While the diarylhydrazones and diaryl Schiff-bases were chosen due to their general biological activity, the carbonyl compounds and phenylhydrazines, that are their precursor compounds, were screened as possible metabolic products. Independent hydrolysis and mass spectrometric studies were also carried out under the generic assay conditions in order to determine the stability of the screened diarylhydrazones and Schiff-bases. The compounds have been tested in standard cytotoxicity assays using Escherichia coli, Micrococcus luteus and Staphylococcus aureus strains. It was observed that the diarylhydrazones showed considerable activity against all three bacterial strains, while the diaryl Schiff-bases exhibited moderate to weak activity. The precursor compounds appeared to be inactive against the bacteria. The stability studies also indicated that the hydrazones as well as the Schiff-bases remained stable under the assay conditions.</p>
dc.identifier.submissionpathcts_retreat/2014/posters/48


Files in this item

Thumbnail
Name:
Horton.pdf
Size:
38.32Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright the Author(s)
Except where otherwise noted, this item's license is described as Copyright the Author(s)